Protocol
12-141
Full Title
A Phase I Study of AC220 for Children with Relapsed or Refractory ALL or AML
Purpose
AC220 is an investigational drug which works by blocking certain targets on cancer cells (enzymes called “receptor tyrosine kinases,” or RTKs). It appears to work best in patients with leukemia who have mutations in the FLT3 gene. Patients with this mutation are less likely to go into remission and more likely to experience a recurrence of their cancer.
In this study, researchers are determining the highest dose of AC220 that can be given safely with the standard drugs cytarabine and etoposide in children with acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) that has returned or persists despite prior therapy, and to assess its preliminary effectiveness. This study is being conducted by the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must be older than 1 month but no older than 21 years of age.
- Patients must have ALL or AML that has returned or persists despite prior therapy.
- Patients must have recovered from the serious side effects of prior therapies prior to entering the study.
For more information about this study and to inquire about eligibility, please contact Dr. Tanya Trippett at 212-639-8267.
Disease(s)
Leukemia
Leukemia: Acute Lymphoblastic Leukemia
Leukemia: Acute Myelogenous Leukemia
Locations
Related Diseases
